Life Sciences

Views from a round table at DCAT Week

Six attendees at this year’s Drug, Chemical & Associate Technologies Association Week in New York for the global bio/pharmaceutical manufacturing value chain gathered at a round table meeting to discuss their participation and share views.



Henny Zijlstra, Chief Commercial Officer, Adragos Pharma, declared she was excited to participate in DCAT Week this year. She explained, “We see this event as an excellent opportunity to engage with our clients, showcase our expanded network in the US market and strengthen relationships with industry peers.

“Our participation at DCAT Week aligns with our strategic approach towards growth, innovation and partnership. We aim to strengthen our market presence, showcase our latest capabilities and present our committed team. In addition to this, our M&A team will be on the look-out for potential acquisition targets.

“We are also excited to unveil the growth of our network, notably the inclusion of two key facilities in Kawagoe and Halden. These developments significantly enhance our service offerings, underlining our dedication to fulfilling the varied needs of our clients.”

According to Joe Compton, Global Business Development, Tjoapack, plans for participation in DCAT reflect the company’s commitment to forging meaningful connections with existing and prospective industry contacts. He said, “Face-to-face meetings will provide our team with an invaluable opportunity to strengthen relationships with our clients and engage with potential new customers.

“We also plan to showcase Tjoapack’s innovative packaging solutions and demonstrate how they can facilitate our clients’ business processes. Our DCAT mission is to highlight Tjoapack’s capability to perform primary packaging and emphasise our expertise in secondary packaging of solid forms and injectables. We aim to showcase our proficiency in handling injectables, making us a reliable partner for companies seeking high-quality packaging solutions.”

He concluded by expressing his hopes and expectations for attendance at DCAT. “These will be instrumental in helping us establish new partnerships and collaborations through face-to-face meetings with potential clients by gaining a deep understanding of their needs. We also aim to strengthen relationships with our existing client base by demonstrating the value of Tjoapack’s solutions.

“Increasing our brand visibility and recognition within the pharmaceutical industry is another important objective at DCAT that will help enhance our market presence. Our team at the event will work hard to gain insights into market trends and customer needs, so we can stay competitive and adapt to evolving market dynamics. Fostering connections, showcasing our expertise and contributing to the industry’s growth and success are our overarching goals for this year’s DCAT.”

Quotient Sciences

Kieron Hall, Chief Marketing Officer, Quotient Sciences, commented, “Driven by strong science and a desire to streamline the drug development process, Quotient Sciences is seen by global pharmaceutical companies and emerging biotechs as a trusted partner. As such, we are excited to participate in this year’s DCAT Week to meet our customers in person and explore an inspiring agenda.

“We’re looking forward to showing our customers how they can achieve even more with custom API synthesis that will further enhance our flagship Translational Pharmaceutics® platform.

“We also plan to use DCAT Week as an opportunity to update our contacts about recent changes to our executive leadership team. Thierry Van Nieuwenhove became Quotient Sciences CEO in October, bringing extensive expertise in small molecules and biologics drug development programs to the business.”

He also announced that Dr Andrew Lewis had been appointed as the organisation’s Chief Scientific Officer, having been with the company for almost a decade, most recently leading its Pharmaceutical Sciences department. Meanwhile, Eric Bironneau had joined as Chief Business Officer, bringing two decades of industry experience, with recent roles at Axplora and Novasep.

He concluded, “This year’s DCAT Week will be a great step on our path to fostering growth and innovation at Quotient Sciences, with the ultimate goal of helping our customers bring new molecules to patients as efficiently as possible. That’s why we are looking forward to seeing our established and prospective clients in New York City with our leadership team”.

Hayley Crowe, Executive Vice President and General Manager, Global Life Sciences, revealed what Purolite, an Ecolab company, will be showcasing at DCAT Week. “As one of the most established and well-attended pharma events globally and while our industry continues to evolve, Ecolab is committed to being at its forefront. DCAT Week offers a great opportunity for networking and the ability to nurture relationships with existing and potential new customers.

“Purolite will be sharing key updates around its new Life Sciences sector offering, which includes solutions covering APIs and excipients, milling media and bioprocessing purification.

“We will also highlight Ecolab’s commitment to life sciences and collaboration through our Pharma Enterprise Solutions team. They will be showcasing our offering to support every step of the drug development journey, as a total solution for Pharma.”

When revealing what Purolite hoped to achieve from the event, she said, “The biopharma sector is very much a people-focused industry and collaboration is key. We’re always looking for new ways to engage with delegates who attend DCAT Week and continue to build our relationships across the value chain. DCAT Week presents a truly global forum to network and help build deeper, more meaningful relationships with fellow executives. This way, attendees of DCAT Week get a real feel for whom we are, the innovative solutions we provide and the culture of our business.

“The main objective for participating in DCAT Week includes engaging with current customers, meeting prospective customers interested in our solutions and presenting Ecolab’s comprehensive capabilities and investments in Purolite. The event is a regular fixture on Purolite’s events calendar, delivering an excellent opportunity to introduce our offering to a broader audience.”

Speaking on behalf of Abzena, Campbell Bunce, PhD, Chief Scientific Officer, set out his plans for DCAT Week. He stated, “This is Abzena’s first attendance at DCAT Week and we have a packed agenda focused on increasing our exposure across the DCAT community and raising awareness of who we are and what we can offer drug developers. We have extensive meetings planned with existing and new customers to establish and strengthen our relationships to generate business for Abzena. We are committed to driving success for our customers to deliver effective new drugs to patients in need. We provide full, end-to-end service offerings for the design, development and manufacture of bioconjugates, including ADCs and complex biologics from early discovery through commercial introduction”.

As to what does Abzena hopes to achieve from the event, he said, “We would like to come away from DCAT Week with a better, more informed sense of what the pain points are for the biotech and pharma community? This will allow us to review, refine and adjust what the sector needs from a solution providing CDMO + CRO like Abzena. The last four years have presented many global events that have driven uncertainty in supply chains, capacity, costs and investment in the sector.

“We hope that the event will provide some direction so we can tailor our offering to give our customers the best value for their money. I hope to come home from DCAT Week having convinced many customers that we are the best-equipped contract organisation to help move their Biologics and Antibody-Drug Conjugates (ADCs) programs forward to their next inflexion point.”


Patrick Thiaville, Nucleic Acids Chief Technology Officer, Exothera, declared that DCAT Week presented a unique platform for Exothera to engage with industry professionals and delve into the latest advancements in pharmaceutical technology. He declared, “At this year’s event, we are thrilled to showcase our nucleic acids service offering, powered by the ground-breaking Ntensify™ RNA production platform.

“While speed is a notable aspect of the Ntensify™ platform, we recognise that the primary concern in RNA manufacturing lies in ensuring consistent quality and yield, particularly during the transition from clinical to commercial production. With Ntensify™, there is no need for process scale-up, ensuring continuity and consistency in production from early-stage development to full-scale commercialisation.

“As an experienced and specialist CDMO we are committed to scientific problem-solving, attentive service and transparent communication at every stage of the process. Our partnership with sister company Quantoom Biosciences grants us exclusive access to the Ntensify™ platform, enabling us to offer our clients the most advanced RNA production service technology available.”